ASKA Pharmaceutical Holdings Co.,Ltd.(4886) News

Personnel Changes of ASKA Pharmaceutical Holdings

Personnel Changes of ASKA Pharma Medical

MICIN and ASKA Enter into Agreement on Joint Development and Marketing of Irritable Bowel Syndrome Treatment App

Notice Concerning Receipt of Statement of Intent for the Large-scale Purchase Actions etc. Pertaining to the Large-scale Purchase etc.

ASKA Obtains Manufacturing and Marketing Approval for LEUPRORELIN ACETATE SR FOR INJECTION KIT

Notice Concerning Completion of Payment for Disposal of Treasury Shares as Remuneration for Restricted Shares

Supplementary Documents for 1Q FY2025

Consolidated Financial Results for the First Quarter of FY2025

ASKA Pharma, Apr-Jun (1Q) Ordinary Profit Decreases by 11%

Notice of Treasury Stock Disposal as Remuneration for Restricted Stock

ASKA to Open ZEB Certified Community Center “arca” at its Iwaki Factory

ASKA Pharmaceutical Holdings Included in FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index

Notice Concerning Establishment of Independent Committee and Appointment of Independent Committee Members

Notice Concerning Introduction of Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Large-scale Purch

ASKA Launches Oral Contraceptive Slinda 28 Tablets in Japan

Change in Corporate Officer’s Responsibilities

ASKA to Initiate Domestic Phase III Clinical Trial of Relugolix Combination Tablet for Endometriosis

Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries

Personnel Changes of Board Members and Corporate Officers

Notice：Appointment of New President